Cancer “vaccines” enter the neoantigen stage
Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
Few safe havens surface in another down quarter for biopharma
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
Brace for an end-of-year boost to drug approvals
The first half of 2022 was slow on the regulatory front, but plenty of big decisions remain for Bristol Myers Squibb, Apellis and others.
